載入中
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
前收盤價
US$9.86
+US$0.34 · +3.57%
盤中時間採用ET。市場資料可能有所延遲。
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
日內區間
目前US$9.86
52週區間
目前US$9.86
盤中時間採用ET。市場資料可能有所延遲。
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
日內區間
目前US$9.86
52週區間
目前US$9.86
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 55.9萬 USD | 4325.8萬 USD | 2537.5萬 USD | 1765.3萬 USD | 1241.5萬 USD |
| 銷貨成本 | 21.5萬 USD | 1181萬 USD | 1031.8萬 USD | 1097.5萬 USD | 745.6萬 USD |
| 毛利 | 34.4萬 USD | 3144.8萬 USD | 1505.7萬 USD | 667.81萬 USD | 495.9萬 USD |
| 研究與開發 | 6775.3萬 USD | 6788.3萬 USD | 4402.5萬 USD | 3550.17萬 USD | 3076.5萬 USD |
| 銷售、一般及管理費用 | 2234.4萬 USD | 2688.4萬 USD | 2063.6萬 USD | 2093.58萬 USD | 2000.8萬 USD |
| 營業費用 | 9009.7萬 USD | 9476.7萬 USD | 6466.1萬 USD | 5643.76萬 USD | 5077.3萬 USD |
| 利息收入 | 348萬 USD | 447.2萬 USD | 144.6萬 USD | 22.6萬 USD | 1萬 USD |
| 利息支出 | — | — | 3.4萬 USD | 4.7萬 USD | 8000 USD |
| 折舊和攤銷 | 55.5萬 USD | 46.33萬 USD | 49.8萬 USD | 49.09萬 USD | 42.51萬 USD |
| 營業利益 | −8975.3萬 USD | −6331.9萬 USD | −4960.4萬 USD | −4975.95萬 USD | −4581.4萬 USD |
| 淨利 | −8861.2萬 USD | −4530.9萬 USD | −4326.7萬 USD | −4103.2萬 USD | −3941萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$57.00
上漲空間 478.09%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB274.22萬0.03%108.2億 USD0.44%US$206.49+3.00%
State Street SPDR S&P International Small Cap ETFGWX20.75萬0.02%9.08億 USD0.40%US$45.56+0.93%
ActivePassive International Equity ETFAPIE10.67萬0.01%11.41億 USD0.45%US$38.56+0.65%
Invesco Nasdaq Biotechnology ETFIBBQ3.5萬0.03%1.12億 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB1.78萬0.02%9320.36萬 USD1.19%US$110.98+5.68%iShares Biotechnology ETFIBBState Street SPDR S&P International Small Cap ETFGWXActivePassive International Equity ETFAPIEInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
